Adocia : Several catalysts in the short term
>Financial visibility out to end-August - Adocia has published its revenue and cash position for Q4 2023. The group has yet to make any sales and its top line is primarily composed of inflows from its partnership agreements. This came in at € 0.2m (vs € 1.7m in Q4 2022) representing invoiced services to its partner Dongbao as part of the three clinical trials in Europe for BC Combo. The cash position at end-December 2023 was € 13m, i.e. cash burn of € 3.8m for the qu...ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.